A Phase 1, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 in Patients With Indolent Systemic Mastocytosis

Trial Profile

A Phase 1, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 in Patients With Indolent Systemic Mastocytosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs AK 002 (Primary)
  • Indications Systemic mastocytosis
  • Focus Adverse reactions
  • Sponsors Allakos
  • Most Recent Events

    • 18 Dec 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2018.
    • 18 Dec 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2018.
    • 15 Sep 2016 According to Allakos media release, Frank Siebenhaar, M.D., of the Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, who, along with Professor Marcus Maurer, M.D., is a principal investigator for this study
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top